Wink Biotherapeutics
Preclinical RNA therapeutics pursuing an injectable functional cure for diabetes
| Deal Type | Equity |
|---|---|
| Sector | BioTech & Life Sciences |
| Geography | United States |
| Stage / Vintage | Seed / preclinical |
| Total Fundraise | USD 3.6M |
| Minimum Ticket | N/D |
Opportunity Overview
Wink Biotherapeutics is developing preclinical, RNA-based functional cures for diabetes, initially through beta-cell-targeting therapeutics licensed from the University of Miami Diabetes Research Institute. The company's lead programmes target pancreatic beta cells, with WT-817 focused on type 1 and type 2 diabetes and WT-931 focused on type 1 diabetes. Wink presents the unmet need as the lack of natural insulin pulsing and the need to regenerate insulin-producing beta cells, positioning targeted beta cell regeneration as a high-value therapeutic goal. The team cites involvement in 10+ drug approvals and seven exits, external expert validation, and early interest from two pharma companies after scientific review.
Key Highlights
- Beta Cell Targeting platform licensed from University of Miami's Diabetes Research Institute.
- Lead assets WT-817 and WT-931 are in preclinical development for diabetes indications.
- Team members have cumulatively played major roles in 10+ drug approvals and seven exits.
- Two pharma companies are said to have expressed initial interest after scientific review.
- USD 3.6M seed ask to fund non-GLP toxicology studies and initial CMC work, with potential matched non-dilutive support from Breakthrough T1D.
GCC Relevance
Diabetes is a major regional healthcare burden, making the therapeutic area highly relevant for GCC strategic healthcare investors. However, the opportunity is preclinical and higher-risk, and the materials do not identify a Middle East development, clinical or commercial partner.